Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Biomarkers for Prostate Cancer Diagnosis From Genetic Perspectives Publisher



Khatami F1 ; Aghamir SMK1 ; Salmaninejad A2 ; Shivarani S1 ; Khorrami MH3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Department of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Translational Research in Urology Published:2020


Abstract

Prostate cancers (PC) are mainly diagnosed by screening prostate-specific antigen (PSA) quantity in the blood or a digital rectal exam (DRE). PC typically does not have symptoms contrary to advanced cancers that are diagnosed due to significant symptoms. Diagnosis of PC is established with the transrectal ultrasound (TRUS) guided biopsy. Estimation of the free PSA to total PSA (fPSA/tPSA) ratio and Multiparametric-magnetic resonance imaging (mp-MRI) can expand the diagnosis accuracy. Several molecular biomarkers have improved PC diagnosis like Confirm MDx, Prostate Core Mitomic Test (PCMT), TMPRSS2-ERG, The PTEN gene, ProMark, 4K score including, and Circulating Tumor Cells (CTCs). These molecular biomarkers are considered both genetic and epigenetic (DNA methylation) hallmarks of PC. We aim to present an overview of all molecular biomarkers of PC and their implication in improving the management of PC patients. © 2020 Urology Research Center (URC).
Related Docs
View other Related Docs
1. Biomarkers for Evaluation of Prostate Cancer Prognosis, Asian Pacific Journal of Cancer Prevention (2015)
2. Multiparametric Magnetic Resonance Imaging of Prostate Cancer: Association of Quantitative Magnetic Resonance Parameters With Histopathologic Findings, Iranian Journal of Radiology (2017)
3. Evaluation of the Accuracy of Dynamic Contrast Enhanced Mri in the Diagnosis of Invasive Prostate Neoplasm Using Pathological Findings, Tehran University Medical Journal (2021)
4. Jpx and Linc00641 Ncrnas Expression in Prostate Tissue: A Case-Control Study, Research in Pharmaceutical Sciences (2021)
5. Discrepancies Between Biopsy Gleason Score and Radical Prostatectomy Specimen Gleason Score: An Iranian Experience, Urology Journal (2019)
6. Exosomal Noncoding Rnas in Prostate Cancer, Clinica Chimica Acta (2022)
7. Relation Between Serum Level of Total Psa and Free Psa/Total Psa Ratio With Grade of Prostate Cancer, Journal of Isfahan Medical School (2013)
8. Liquid Biopsy in Prostate Cancer Diagnosis and Prognosis: A Narrative Review, Translational Research in Urology (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Yazdani (5)
Mehrdad Mohammadi Sichani (2)
Other Related Docs
9. Whole-Body Low-Dose Ct Can Be of Value in Prostate Cancer Decision-Making: A Retrospective Study on 601 Patients, Insights into Imaging (2023)
10. Diagnostic Values of Serum Total Prostate-Specific Antigen for Detection of Breast Masses Nature in 20-75-Year-Old Women With Breast Mass, Journal of Isfahan Medical School (2017)
11. The Utility of Stat6 and Aldh1 Expression in the Differential Diagnosis of Solitary Fibrous Tumor Versus Prostate-Specific Stromal Neoplasms, Human Pathology (2016)
12. Exploring the Efficacy of Multi-Flavored Feature Extraction With Radiomics and Deep Features for Prostate Cancer Grading on Mpmri, BMC Medical Imaging (2023)
13. Phosphatase and Tensin Gene Association With Features of Aggressive Prostate Cancer, Translational Research in Urology (2021)
14. Perineural Invasion, Gleason Score and Prostate Specific Antigen; Is There Any Association?, Journal of Nephropathology (2019)
15. Rate of Clinically Significant Prostate Cancer on Repeated Biopsy After a Diagnosis of Atypical Small Acinar Proliferation, Immunopathologia Persa (2023)
16. Diagnostic Yield of Fusion Magnetic Resonance-Guided Prostate Biopsy Versus Cognitive-Guided Biopsy in Biopsy-Naive Patients: A Head-To-Head Randomized Controlled Trial, Prostate Cancer and Prostatic Diseases (2021)
17. Investigation of Prostate Disorders in 614 Patients Attended Alzahra/Urology Ward Between the Years 2013 to 2015 in Isfahan, International Journal of Pharmaceutical and Clinical Research (2016)
18. New Gleason Grade Groups; Epidemiologic Data From Isfahan, Iran Based on the New Classification, Immunopathologia Persa (2022)
19. Evaluation of Neuroendocrine and Proliferative Markers in Prostatic Adenocarcinomas, Iranian Journal of Medical Sciences (2006)
20. Incidental Prostate Cancer: A 10-Year Review of a Tertiary Center, Tehran, Iran, Research and Reports in Urology (2018)